ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer's Readout Ahead [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
ACADIA Pharmaceuticals (NASDAQ:ACAD) highlighted its growing commercial portfolio, upcoming clinical catalysts, and cash position during a presentation at the Citizens Life Sciences Conference, with remarks from CFO Mark Schneyer and Head of Clinical Development Srdjan Stankovic. Commercial portfolio surpasses $1 billion in net sales Schneyer said the company's two commercial-stage products, NUPLAZID (for Parkinson's disease psychosis) and DAYBUE (for Rett syndrome), have combined for more than $1 billion in net sales for the first time in company history. He added that ACADIA's guidance at the midpoint is about $1.25 billion for the year. ? Microsoft Positioned to Win AI Race With Dual-Model Strategy Schneyer also emphasized ACADIA's balance sheet and cash generation, stating the company is cash flow positive with more than $800 million in cash and no debt Remlifanserin Alzheimer's disease psychosis data expected in late summer/early fall On the pipeline, Schneyer and St
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year [Yahoo! Finance]Yahoo! Finance
- Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumBusiness Wire
ACAD
Earnings
- 2/25/26 - Beat
ACAD
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 3
- 3/10/26 - Form 4
- ACAD's page on the SEC website